Cat Living 30 Years


The leading cause of death in cats is kidney disease and complications associated with the disease.

Greycoat Research strives to extend the lives of cats while ensuring they remain happy and healthy through it all. We hope that one day, every cat will be able to celebrate its 30th birthday.

Read Our Story

What is AIM?

AIM (Apoptosis Inhibitor of Macrophage) is a blood protein first discovered by Dr. Toru Miyazaki. Under healthy conditions, AIM exists at approximately 5 μg/mL in the bloodstream and generally remains inactive and bound to a type of antibody known as Immunoglobulin M (IgM). When activated, AIM will bind to various types of waste, such as cellular debris, damaged proteins, or inflammatory molecules released by dead cells, and serve as a marker to signal the waste for cleanup. This cleanup process helps protect the body from developing diseases.

In cats, however, the AIM is unable to properly activate and detach from IgM. This means that the AIM is unable to trigger the disposal of waste in the kidneys, resulting in cats becoming susceptible to kidney disease and chronic inflammation. Dr. Toru Protocol helps trigger the activation of AIM in cats’ bodies, thereby facilitating the cleanup of waste in their bodies to prevent feline kidney disease.

The Institute for AIM Medicine

Dr. Toru Miyazaki

  • Graduated from the University of Tokyo School of Medicine in 1986
  • Worked as a researcher at the Louis Pasteur University of Strasbourg/IGBMC (France) from 1992
  • Principal Researcher at the Basel Institute for Immunology (Switzerland) from 1995
  • Associate Professor at Center for Immunology at the University of Texas Southwestern Medical Center at Dallas (USA) from 2000
  • Served as a professor at the Graduate School of Medicine, University of Tokyo, from 2006 to 2022
  • Working as the President and Director of the Institute for AIM Medicine (IAM)
Find Out More